BioRestorative Therapies (BRTX) Income from Continuing Operations (2010 - 2025)

BioRestorative Therapies (BRTX) has 16 years of Income from Continuing Operations data on file, last reported at 26409300.0 in Q4 2025.

• Quarterly Income from Continuing Operations fell 866.17% year-over-year to 26409300.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 39167064.0 (down 233.85% YoY) and the FY2025 annual result came in at 38231132.0, up 6.73% from the prior year.
• Income from Continuing Operations eased to 26409300.0 in Q4 2025, from 3709011.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 2287844.0 in Q3 2024 to a low of 26409300.0 in Q4 2025.
• A 5-year average of 5643684.3 and a median of 4161450.5 in 2021 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2021 — Income from Continuing Operations tumbled 1178.06% — and 2022, when it soared 66.25%.
• Tracing BRTX's Income from Continuing Operations over 5 years: stood at 4048860.0 in 2021, then decreased by 16.64% to 4722687.0 in 2022, then surged by 30.91% to 3262689.0 in 2023, then advanced by 16.22% to 2733407.0 in 2024, then plunged by 866.17% to 26409300.0 in 2025.
• The last three Income from Continuing Operations figures came in at 26409300.0 (Q4 2025), 3709011.0 (Q3 2025), and 3675131.0 (Q2 2025), per Business Quant data.